[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"kidney-calculi\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:kidney-calculi":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,59,90,118,145,175,194,210,238,268,293,314,330,347,371],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100645126","access-sheaths-with-aspiration-for-renal-retrograde-surgery-randomized-comparative-outcomes-100645126",false,"NCT07678255","Access Sheaths With Aspiration for Renal RetrOgrade Surgery, Randomized CompArative Outcomes","ACCESS SHEATHS WITH ASPIRATION FOR RETROGRADE RENAL SURGERY, RANDOMIZED COMPARATIVE OUTCOMES","ARROCA01","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of intrarenal lithiasis with maximum stone diameter of 1-3 cm on preoperative non-contrast abdomino-pelvic CT scan\n* Candidate for treatment by flexible ureteroscopy (RIRS) as indicated by the treating urologist\n* Attended at the Department of Urology, Hospital Universitario Virgen del Rocío (Seville, Spain)\n* Willing and able to provide written informed consent\n* Able to comply with the study follow-up schedule (CT scan at 1 and 3 months post-intervention)\n\nExclusion Criteria:\n\n* Active urinary tract infection or urosepsis at the time of the planned intervention\n* Known ureteral stricture precluding passage of a ureteral access sheath\n* Pregnancy\n* Prior urinary diversion incompatible with transurethral access (e.g., urinary conduit, neobladder)\n* Bleeding disorder or anticoagulant\u002Fantiplatelet therapy that cannot be safely interrupted perioperatively\n* Stone diameter \\\u003C1 cm or \\>3 cm on preoperative CT\n* Inability to provide informed consent (cognitive impairment, language barrier without interpreter availability)\n* Simultaneous participation in another clinical trial that could interfere with the outcomes of this study","ALL","18 Years",{"count":20,"type":21},156,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn whether the ClearPetra ureteral access sheath (Coloplast) is more effective than the Navigator ureteral access sheath (Boston Scientific) in treating intrarenal kidney stones of 1-3 cm in adult patients undergoing flexible ureteroscopy (RIRS). The main questions it aims to answer are:\n\nDoes ClearPetra achieve a higher stone-free rate at 1 month post-intervention compared to Navigator, as assessed by non-contrast abdominal-pelvic CT scan?\n\nDoes ClearPetra reduce total surgical time compared to Navigator?\n\nDoes ClearPetra lower the retreatment rate at 3 months compared to Navigator?\n\nDoes ClearPetra present a rate of clinically significant complications (Clavien-Dindo ≥ II) that is lower than or similar to Navigator?\n\nResearchers will compare flexible ureteroscopy using the ClearPetra vacuum-assisted flexible ureteral access sheath to flexible ureteroscopy using the Navigator standard rigid ureteral access sheath, to see if ClearPetra leads to higher stone clearance rates while maintaining a comparable safety profile.\n\nParticipants will:\n\nUndergo flexible ureteroscopy (RIRS) using one of two randomly assigned ureteral access sheaths (ClearPetra or Navigator), determined by computer-generated randomization immediately before surgery\n\nHave a non-contrast abdominal-pelvic CT scan at 1 month post-intervention to assess stone-free status\n\nHave a non-contrast abdominal-pelvic CT scan at 3 months post-intervention to evaluate residual fragments and the need for retreatment\n\nAttend follow-up visits at 1 month and 3 months post-surgery for clinical assessment and complication recording\n\nThe study will be conducted at the Urology Department of Hospital Universitario Virgen del Rocío (Seville, Spain), a tertiary reference centre. A total of 156 patients will be randomized in a 1:1 ratio (78 per group), with pre-defined subgroup analyses stratified by stone size (1-2 cm vs. \\>2 cm). The outcome assessor evaluating CT images for stone-free rate will be blinded to treatment allocation (single-blind).",[27,28,29,30],"Urolithiasis","Nephrolithiasis","Kidney Calculi","Ureteroscopy",[32,33,34,35,36,37,38,39,40,41,42,43,44,45],"Flexible ureteroscopy","Retrograde intrarenal surgery","RIRS","Ureteral access sheath","ClearPetra","Navigator","Stone-free rate","Laser lithotripsy","Intrarenal lithiasis","Vacuum-assisted sheath","Clavien-Dindo","Stone fragmentation","Endourology","Urinary tract calculi","NOT_YET_RECRUITING","2026-06-25",{"date":49,"type":50},"2026-07-01","ACTUAL",{"date":52,"type":21},"2026-09-15",{"date":54,"type":21},"2030-05",{"name":56,"class":57},"Hospitales Universitarios Virgen del Rocío","OTHER",1,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":22,"phases":68,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":89},"100641920","antibiotic-irrigation-and-suction-ureteral-access-sheath-in-rirs-100641920","NCT07655050","Antibiotic Irrigation and Suction Ureteral Access Sheath in RIRS","The Combined Effect of Antibiotic Irrigation and Aspiration Ureteral Access Sheath on Infectious Complications in Retrograde Intrarenal Surgery: A Prospective Randomized Factorial Study","Inclusion Criteria:\n\n* Patients scheduled for retrograde intrarenal surgery (RIRS) due to kidney stones\n* Male and female patients aged 18 years or older\n* Patients who voluntarily sign the informed consent form\n* Patients with sterile urine culture or whose preoperative infection has been treated and urine culture has become sterile\n\nExclusion Criteria:\n\n* Patients with active urinary tract infection before surgery\n* Patients with chronic kidney disease\n* Pregnant patients\n* Patients with allergy to aminoglycoside-group drugs used in the study protocol, specifically gentamicin\n* Cases in which the ureter cannot be accessed and the procedure is postponed by placing a double-J stent instead of performing dilation",{"count":67,"type":21},180,[24],"Retrograde intrarenal surgery (RIRS) is a widely used treatment for kidney stones; however, postoperative infectious complications remain a significant concern. This prospective randomized factorial trial aims to evaluate whether gentamicin-containing irrigation fluid and the use of a suction ureteral access sheath can reduce postoperative fever, systemic inflammatory response syndrome (SIRS), and sepsis after RIRS. The study will also investigate the independent and combined effects of these two interventions on infectious outcomes.",[29,27,71],"Urinary Tract Infections",[33,73,74,75,76,77,78],"Kidney stone","Gentamicin","Irrigation fluid","Infectious complications","Urinary tract infection","SEPSİS","RECRUITING","2026-06-21",{"date":82,"type":50},"2026-06-24",{"date":84,"type":50},"2026-06-15",{"date":86,"type":21},"2027-05-08",{"name":88,"class":57},"Hitit University",2,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":100,"briefSummary":101,"conditions":102,"keywords":103,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":58},"100637205","supine-vs-prone-pcnl-for-large-renal-stones-a-randomized-trial-in-yemen-100637205","NCT07627503","Supine vs. Prone PCNL for Large Renal Stones: A Randomized Trial in Yemen.","Comparative Evaluation of Early Postoperative Complications, Cost-Effectiveness, and Patient-Centered Outcomes Following Supine and Prone Standard Percutaneous Nephrolithotomy (PCNL): A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients aged 18-70 years.\n* Diagnosis of solitary or multiple renal stones with a cumulative diameter greater than 2 cm, confirmed by imaging (CT KUB).\n* Patients eligible for standard PCNL (24-30 Fr).\n* American Society of Anesthesiologists (ASA) physical status I-III.\n* Willingness and ability to provide informed consent.\n\nExclusion Criteria:\n\n* Patients with active urinary tract infection (UTI) not responding to antibiotics.\n* Patients with bleeding diathesis or on anticoagulant therapy that cannot be safely discontinued.\n* Patients with anatomical abnormalities of the kidney or urinary tract that preclude standard PCNL.\n* Pregnant women.\n* Patients with severe cardiopulmonary disease where general anesthesia or prolonged surgical positioning is contraindicated.\n* Patients with a history of previous ipsilateral renal surgery.\n* Patients unwilling or unable to comply with follow-up protocols.","70 Years",{"count":99,"type":21},140,[24],"The goal of this clinical trial is to compare the safety, cost-effectiveness, and patient recovery of two different surgical positions for percutaneous nephrolithotomy (PCNL) in adults aged 18 to 70 years who have kidney stones larger than 2 cm. The main questions it aims to answer are:\n\n* Does the supine (lying on the back) surgical position result in fewer early postoperative complications than the traditional prone (lying on the stomach) position?\n* Does the supine position reduce the total surgery time, direct hospital costs, and postoperative pain?\n\nResearchers will compare patients assigned to undergo PCNL in the supine position to those assigned to the prone position to see if the supine approach offers a safer, more cost-effective, and more comfortable recovery.\n\nParticipants will:\n\n* Undergo standard PCNL surgery to remove their kidney stones in either the supine or prone position.\n* Have their pain levels, surgery time, and any early surgical complications monitored during their hospital stay.\n* Complete brief questionnaires regarding their overall surgical satisfaction and quality of life at 1 month and 3 months after the procedure.",[29,28],[104,105,106,107,108],"PCNL","Percutaneous Nephrolithotomy","Kidney Stones","Supine PCNL","Prone PCNL","2026-06-03",{"date":111,"type":50},"2026-06-05",{"date":113,"type":21},"2026-06-01",{"date":115,"type":21},"2027-06-30",{"name":117,"class":57},"Sana'a University",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":129,"phases":4,"briefSummary":130,"conditions":131,"keywords":132,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":142,"locationsCount":144},"100638554","iau-percutaneous-nephrolithotripsy-study-100638554","NCT07622238","IAU Percutaneous Nephrolithotripsy Study","International Alliance of Urolithiasis Percutaneous Nephrolithotripsy Study","IAUPCNL","Inclusion Criteria:\n\n* Patient age 18 years or older at the time of enrollment.\n* Diagnosed with single or multiple renal calculi (including complex and staghorn calculi) or proximal ureteral stones.\n* Scheduled to undergo any primary or secondary percutaneous surgical stone intervention, including standard percutaneous nephrolithotomy (PCNL) or any of its miniaturized variations (Mini-PCNL, Ultra-mini PCNL, Super-mini PCNL, or Micro-PCNL).\n* Voluntarily provided written informed consent for participation and data utilization.\n\nExclusion Criteria:\n\n* Patient age under 18 years.\n* Patients scheduled to undergo alternative primary treatment modalities for the targeted stone burden as a standalone procedure (e.g., retrograde intrarenal surgery \\[RIRS\\] or shockwave lithotripsy \\[SWL\\]).\n* Presence of an active, untreated urinary tract infection (UTI) or clinical urosepsis at the time of the scheduled surgical procedure.\n* Uncorrected severe coagulopathy or uncorrectable bleeding diathesis.\n* Missing, incomplete, or unavailable medical charts or follow-up records rendering outcome assessment impossible.","100 Years",{"count":128,"type":21},4000,"OBSERVATIONAL","During the past 10-15 years, important advancements have been witnessed in percutaneous nephrolithotomy (PCNL) techniques and instrumentation. The development of miniaturized PCNL techniques and modern laser technologies has contributed to lower complication rates, alongside changes in exiting strategies and postoperative drainage protocols. Ultrasound is increasingly utilized to create percutaneous access, and many medical centers have transitioned to the supine position for PCNL or perform Endoscopic Combined Intrarenal Surgery (ECIRS). All these developments have helped to individualize treatment strategies and to improve clinical outcomes for patients. However, there remains an ongoing discussion regarding the optimal indications and limitations of the different miniaturized PCNL techniques compared to standard PCNL and retrograde intrarenal surgery (RIRS).\n\nThis prospective observational study is organized under the auspices of the International Alliance of Urolithiasis (IAU) and focuses on the contemporary indications, surgical techniques, instrumentation, exiting strategies, efficacy, and risk factors for intraoperative and postoperative complications of PCNL. Participating investigators will collect data on the PCNL procedures performed in their respective clinical centers prospectively for a period of 12-18 months. The study will be initiated in each clinical center following formal approval from the IAU Scientific Committee, which will also announce the conclusion of the study.",[27,29],[105,133,134,27,106,135,136],"Standart PCNL","Mini-PCNL","Postoperative Complications","Efficacy","2026-05-30",{"date":109,"type":50},{"date":140,"type":50},"2019-08-15",{"date":84,"type":21},{"name":143,"class":57},"Foundation Endourology",4,{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":152,"sex":17,"minAge":18,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":22,"phases":156,"briefSummary":157,"conditions":158,"keywords":164,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":89},"100592122","endogenous-oxalate-synthesis-in-idiopathic-calcium-oxalate-kidney-stone-disease-100592122","NCT06989320","Endogenous Oxalate Synthesis in Idiopathic Calcium Oxalate Kidney Stone Disease","Endogenous Oxalate Synthesis in Idiopathic Calcium Oxalate Kidney Stone Formers","Inclusion Criteria:\n\n* age 18-80 yrs\n* Body Mass Index \\> 18.5 kg\u002Fm2\n* Normal fasting serum electrolytes on comprehensive metabolic profile\n* Willing to ingest fixed diets\n* Willing to stop supplements (vitamins including vitamin C, calcium (citrate or carbonate) and other minerals, herbal supplements, nutritional aids, probiotics) for 2 weeks before start and during study.\n* For stone formers: first time or recurrent Calcium Oxalate stone former. Composition of most recent stone ≥ 50% calcium oxalate if available, uric acid component \\\u003C20%\n\nExclusion Criteria:\n\n* Chronic Kidney Disease stage 4-5\n* Primary hyperoxaluria, Enteric (secondary) hyperoxaluria\n* Liver, bowel, endocrine or renal diseases (other than idiopathic Calcium Oxalate kidney stones) or any other condition that may influence the absorption, transport or urinary excretion of ions, which will compromise the interpretation of results, including: Cystic fibrosis, Celiac disease, Cystinuria, Uric acid stone former, Nephrotic syndrome, Sarcoidosis, Renal tubular acidosis, Primary hyperparathyroidism, Neurogenic bladder, Urinary diversion, Chronic diarrhea, Bariatric surgery, Inflammatory bowel disease\n* Pregnancy or breast-feeding\n* Incompatible dietary requirements with the study, food allergies or intolerance to any of the foods in study menus\n* Active malignancy or treatment for malignancy within 12 months prior to screening\n* Utilization of immunosuppressive medication\n* Uncontrolled hypertension or diabetes\n* Diabetes type 1",true,"80 Years",{"count":155,"type":21},80,[24],"The goal of this clinical trial study is to test if patients with idiopathic calcium oxalate kidney stones have an increased production of oxalate by the body, which would lead to increased urinary excretion of oxalate.\n\nThe study will recruit adult patients with a history of calcium oxalate kidney stones and healthy volunteers without kidney stones.\n\nParticipants will\n\ningest fixed diets containing low amounts of oxalate for 5 days ingest a soluble form of glycolate and vitamin C collect urine, blood, stool during the dietary and oral dosing portions of the study and also collect breath sample during the oral glycolate test",[106,29,27,159,28,160,161,162,163],"Urolithiasis, Calcium Oxalate","Nephrolithiasis, Calcium Oxalate","Oxalate Urolithiasis","Healthy","Healthy Volunteer",[165],"oxalate synthesis","2026-05-27",{"date":168,"type":50},"2026-05-29",{"date":170,"type":50},"2025-05-27",{"date":172,"type":21},"2031-12-31",{"name":174,"class":57},"University of Alabama at Birmingham",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":152,"sex":17,"minAge":18,"maxAge":97,"enrollmentInfo":182,"targetDuration":4,"studyType":22,"phases":183,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":193,"locationsCount":89},"100541567","gut-oxalate-absorption-in-calcium-oxalate-stone-disease-100541567","NCT06331546","Gut Oxalate Absorption in Calcium Oxalate Stone Disease","Gastrointestinal Oxalate Absorption in Calcium Oxalate Stone Disease","Inclusion Criteria:\n\n* age 18-70 yrs\n* Body Mass Index \\> 18.5 kg\u002Fm2\n* Normal fasting serum electrolytes on comprehensive metabolic profile\n* Willing to ingest fixed diets\n* Willing to stop supplements (vitamins including vitamin C, calcium (citrate or carbonate) and other minerals, herbal supplements, nutritional aids, probiotics) for 2 weeks before start and during study.\n* For stone formers: first time or recurrent Calcium Oxalate stone former. Composition of most recent stone ≥ 50% calcium oxalate if available, uric acid component \\\u003C20%\n\nExclusion Criteria:\n\n* Chronic Kidney Disease stage 4-5\n* Primary hyperoxaluria, Enteric (secondary) hyperoxaluria\n* Liver, bowel, endocrine or renal diseases (other than idiopathic Calcium Oxalate kidney stones) or any other condition that may influence the absorption, transport or urinary excretion of ions, which will compromise the interpretation of results, including: Cystic fibrosis, Celiac disease, Cystinuria, Uric acid stone former, Nephrotic syndrome, Sarcoidosis, Renal tubular acidosis, Primary hyperparathyroidism, Neurogenic bladder, Urinary diversion, Chronic diarrhea, Bariatric surgery, Inflammatory bowel disease\n* Pregnancy or breast-feeding\n* Incompatible dietary requirements with the study, food allergies or intolerance to any of the foods in study menus\n* Active malignancy or treatment for malignancy within 12 months prior to screening\n* Utilization of immunosuppressive medication\n* Uncontrolled hypertension or diabetes\n* Diabetes type 1\n* Chronic NSAID use",{"count":155,"type":21},[24],"The goal of this clinical trial study is to test if patients with idiopathic calcium oxalate kidney stones have an increased absorption of dietary oxalate, which would lead to increased urinary excretion of oxalate.\n\nThe study will recruit adult patients with a history of calcium oxalate kidney stones and healthy volunteers without kidney stones.\n\nParticipants will\n\n* ingest fixed diets containing low and moderately high amounts of oxalate for 5 days at a time\n* ingest a soluble form of oxalate and sugar preparations to test gut permeability\n* collect urine, blood, stool and breath sample during the fixed diets and the soluble oxalate test",[186,29,27,159,28,160,161,187,162],"Kidney Stone","Oxaluria",{"date":189,"type":50},"2026-05-28",{"date":191,"type":50},"2024-04-17",{"date":172,"type":21},{"name":174,"class":57},{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":97,"enrollmentInfo":201,"targetDuration":4,"studyType":22,"phases":203,"briefSummary":204,"conditions":205,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":206,"startDateStruct":207,"completionDateStruct":208,"leadSponsor":209,"locationsCount":89},"100541467","o-formigenes-colonization-in-calcium-oxalate-kidney-stone-disease-100541467","NCT06330246","O. Formigenes Colonization in Calcium Oxalate Kidney Stone Disease","Oxalobacter Formigenes Colonization in Calcium Oxalate Kidney Stone Formers","Inclusion Criteria\n\n* age 19-70 yrs\n* Body Mass Index \\> 18.5 kg\u002Fm2\n* First time or recurrent Calcium Oxalate stone former. Composition of most recent stone ≥ 50% calcium oxalate if available\n* Not colonized with Oxalobacter formigenes\n* Normal fasting serum electrolytes on comprehensive metabolic profile\n* Willing to ingest fixed diets\n* Willing to stop supplements (vitamins including vitamin C, calcium (citrate or carbonate) and other minerals, herbal supplements, nutritional aids, probiotics) for 2 weeks before start and during fixed diet phases.\n* If on medications for stone prevention (e.g. thiazides, citrate, allopurinol), stable dose regimen for at least 2 weeks prior to and during study\n\nExclusion Criteria\n\n* Chronic Kidney Disease stage 4-5\n* Primary hyperoxaluria\n* Liver, endocrine or renal diseases (other than idiopathic Calcium Oxalate kidney stones) or any other condition that may influence the absorption, transport or urinary excretion of ions, which will compromise the interpretation of results, including: Cystic fibrosis, Cystinuria, Uric acid stone former, Nephrotic syndrome, Sarcoidosis, Renal tubular acidosis, Primary hyperparathyroidism, Neurogenic bladder, Urinary diversion\n* Pregnancy or breast-feeding\n* Incompatible dietary requirements with the study, food allergies or intolerance to any of the foods in study menus\n* Active malignancy or treatment for malignancy within 12 months prior to screening\n* Utilization of immunosuppressive medication\n* Uncontrolled Hypertension or diabetes\n* Diabetes type 1\n* Current Colonization with Oxalobacter formigenes",{"count":202,"type":21},40,[24],"The goal of this trial is to test if colonization with the gut bacteria Oxalobacter formigenes leads to a reduction in urinary oxalate excretion in patients with calcium oxalate kidney stone disease.\n\nThe study will recruit adult participants with a history of calcium oxalate kidney stones who are not colonized with Oxalobacter formigenes.\n\nParticipants will\n\n* ingest fixed diets containing low and moderately high amounts of oxalate for 4 days at a time\n* collect urine, blood and stool samples during the fixed diets\n* ingest a preparation of live Oxalobacter formigenes to induce colonization with Oxalobacter formigenes",[186,29,27,159,28,160,161,187],{"date":189,"type":50},{"date":191,"type":50},{"date":172,"type":21},{"name":174,"class":57},{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":217,"enrollmentInfo":218,"targetDuration":4,"studyType":22,"phases":220,"briefSummary":221,"conditions":222,"keywords":225,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":237},"100635674","an-international-multicenter-clinical-study-on-application-of-uromed-ai-doctor-based-on-large-language-models-100635674","NCT07555756","An International Multicenter Clinical Study on Application of UroMed AI Doctor Based on Large Language Models","AN INTERNATIONAL MULTICENTER CLINICAL STUDY ON APPLICATION OF UROMED AI DOCTOR BASED ON LARGE LANGUAGE MODELS","Inclusion Criteria:\n\n* Diagnosed with kidney stones, benign prostatic hyperplasia, or bladder cancer in line with the Chinese Guidelines for the Diagnosis and Treatment of Urological and Andrological Diseases (2022 Edition) and requiring hospitalization for surgery.\n\nAged 18 to 60 years with good communication skills. Voluntarily agrees to participate in the clinical study and has signed the informed consent form.\n\nExclusion Criteria:\n\n* Suffers from psychiatric disorders. Refuses to participate in medical activities involving the use of artificial intelligence systems.\n\nUnable to engage in effective communication with the research team. Has multiple underlying diseases with unstable clinical conditions.","60 Years",{"count":219,"type":21},1080,[24],"This study evaluates our team's urology-specific AI (UroMed AI Doctor) for its safety, professionalism, knowledge and Q\\&A ability, and tests its effectiveness against traditional manual urology care, to confirm if it can be a safe auxiliary tool and improve patients' preoperative experience.\n\nBefore the study, we will test the AI with urology questions, compare it to international AI models (DeepSeek, ChatGPT, Google Gemini), and have two senior chief physicians evaluate it.\n\nIn the clinical trial, patients at The First Affiliated Hospital of Guangxi Medical University will be randomly split into two groups: AI-assisted care or traditional care by a specialist.\n\nTwo senior specialists will evaluate both groups blindly; each group will get preoperative education (AI or physician), with anxiety and satisfaction surveyed.\n\nSubsequently, a multi-center validation will be conducted with 11 domestic and international hospitals.",[29,223,224],"Prostatic Hyperplasia","Urinary Bladder Neoplasms",[226,227],"UroMed AI Doctor","Urology","2026-04-21",{"date":230,"type":50},"2026-04-29",{"date":232,"type":21},"2026-05-01",{"date":234,"type":21},"2029-07-31",{"name":236,"class":57},"First Affiliated Hospital of Guangxi Medical University",5,{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":97,"enrollmentInfo":246,"targetDuration":4,"studyType":22,"phases":248,"briefSummary":249,"conditions":250,"keywords":251,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":58},"100623213","metaphylaxis-of-infected-kidney-stones-after-percutaneous-nephrolithotripsy-100623213","NCT07393711","Metaphylaxis of Infected Kidney Stones After Percutaneous Nephrolithotripsy","Evaluation of the Effectiveness of Intrarenal Dioxidine Metaphylaxis for Preventing Recurrence of Infection Stones After Percutaneous Nephrolithotripsy","DIOX-PCNL","Inclusion Criteria:\n\nAge ≥18 years\n\nPatients undergoing percutaneous nephrolithotripsy (PCNL)\n\nInfection-related kidney stones\n\nAbility to provide written informed consent\n\nExclusion Criteria:\n\nAge \\\u003C18 years\n\nPregnancy or breastfeeding\n\nKnown hypersensitivity to dioxidine\n\nSevere renal insufficiency or end-stage renal disease\n\nSevere comorbid conditions that preclude participation",{"count":247,"type":21},95,[24],"Kidney stone recurrence, particularly infection-related stones, remains a significant clinical problem after percutaneous nephrolithotripsy (PCNL). Bacterial colonization and persistent infection are recognized contributors to stone recurrence.\n\nThis study evaluates the effectiveness of intrarenal dioxidine instillation as a metaphylactic measure to reduce recurrence of infection-related kidney stones following PCNL. Patients undergoing PCNL will receive standard treatment, with or without adjunctive intrarenal dioxidine administration. The study aims to assess whether this approach reduces stone recurrence and infection-related complications.",[29,28,71],[252,104,253,254,255,256,257,258],"Percutaneous nephrolithotomy","Infection stones","Struvite stones","Dioxidine","Intrarenal instillation","Stone recurrence","Metaphylaxis","2026-02-08",{"date":261,"type":50},"2026-02-11",{"date":263,"type":21},"2026-03-01",{"date":265,"type":21},"2026-12-30",{"name":267,"class":57},"West Kazakhstan Marat Ospanov Medical University",{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":275,"targetDuration":4,"studyType":22,"phases":277,"briefSummary":279,"conditions":280,"keywords":281,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":289,"leadSponsor":291,"locationsCount":4},"100579039","phase-1-role-of-medication-in-making-urine-less-acidic-as-part-of-kidney-stone-prevention-100579039","NCT06819111","Role of Medication in Making Urine Less Acidic as Part of Kidney Stone Prevention","Kinetics of Urinary Alkalinization Therapy in Patients With Nephrolithiasis","Inclusion Criteria:\n\n* adults, 18 years or older\n* recurrent stone formers or first-time stone formers at high risk for recurrence\n* have a baseline 24-hour urine within six months from study enrollment\n* have the ability to adhere to a directed diet\n\nExclusion Criteria:\n\n* minors (age \\\u003C18 years)\n* mentally incapacitated and\u002For unable to provide consent\n* prisoners\n* pregnant or breastfeeding individuals\n* concurrent potassium citrate therapy\n* concurrent thiazide therapy\n* chronic kidney disease (eGFR \\\u003C60)\n* solitary kidney\n* unable to take any of the study medications due to a prior adverse reaction or other health-related reason (ex: severe renal impairment, hyperkalemia, or severe acidosis or alkalosis).",{"count":276,"type":21},20,[278],"PHASE1","Diet and medications are the cornerstones of kidney stone prevention. Potassium citrate is a commonly prescribed medication to help prevent kidney stones by making urine less acidic. There are different forms of potassium citrate such as over-the-counter tablet or powder, and slow-release tablets that require a prescription. However, it is unknown if one form is better than the others. Therefore, we want to compare different forms of potassium citrate and find out how well they work and whether patients prefer one form over the others.\n\nThe study period will last approximately 6 weeks for each participant. Patients will be instructed to take one form of potassium citrate for one week at a time followed by a washout period for one week. This process will be completed a total of three times as we seek to study the effects of three forms of potassium citrate.\n\nAt the end of each trial week patients will be asked to provide urine samples and complete two surveys. Urine will need to be collected for 24 hours, which will then be examined to determine the effects that each form of potassium citrate has on urine. In addition, completed surveys will give us information on how well the medication was tolerated and their satisfaction with the treatment. There is a possibility that patients like one form better than others, and it is also possible that they do not see a difference at all.\n\nThroughout the duration of the study patients will be asked to be a directed diet. This will be based on general recommendations by the National Kidney Foundation for the prevention of kidney stones.",[29],[282,283,284],"kidney stone prevention","potassium citrate","urine alkalization","2026-02-03",{"date":287,"type":50},"2026-02-05",{"date":49,"type":21},{"date":290,"type":21},"2027-10-31",{"name":292,"class":57},"University of Texas Southwestern Medical Center",{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":152,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":300,"targetDuration":4,"studyType":129,"phases":4,"briefSummary":302,"conditions":303,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":4},"100596278","impact-of-humid-heat-on-gut-tryptophan-stone-pathway-100596278","NCT07043374","Impact of Humid-Heat on Gut-Tryptophan-Stone Pathway","A Mechanistic Study on How Humid and Hot Environment Promotes Urinary Tract Stone Formation Through Influencing Gut Microbiota and Tryptophan Metabolism","Inclusion Criteria:\n\n* Inclusion criteria for patients with kidney stones\n\n  * Age\\>=18 years;\n  * Diagnosed with kidney stones by ultrasound, CT or urography;\n  * Willing to provide stool samples and serum samples for study;\n  * No history of antimicrobial use in the past 3 months;\n  * Signed and dated informed consent indicating that the patient or his\u002Fher legal representative is fully informed of the study-related information and agrees to participate.\n* Inclusion criteria for the healthy control group\n\n  * Age\\>=18 years;\n  * No history of kidney stones and family history;\n  * Imaging examination (such as abdominal ultrasound) showed no kidney stones;\n  * Willing to provide stool samples and serum samples for research;\n  * No history of antibiotic use in the past 3 months;\n  * Signed and dated informed consent indicating that the volunteer is fully informed about the study-related information and agrees to participate.\n\nExclusion Criteria:\n\n* Use of antimicrobials or probiotics within the past 3 months;\n* Presence of active urinary tract infection;\n* Presence of other serious systemic diseases, such as hepatic or renal insufficiency, cardiac or pulmonary diseases, malignant tumors, and immunodeficiency states;\n* Congenital urinary tract abnormalities;\n* Previous history of kidney transplantation or urinary diversion surgery;\n* Pregnant or lactating women;\n* Presence of chronic intestinal diseases, such as inflammatory bowel disease, irritable bowel syndrome, etc.;\n* Inability to provide samples or complete follow-up according to the research protocol;\n* Participation in other clinical studies within the past 3 months;\n* Other conditions deemed unsuitable for participation in this study by the researcher.",{"count":301,"type":21},270,"Investigating the differences in gut microbiota composition and tryptophan metabolite levels between kidney stone patients and healthy individuals, with special focus on:\n\n1. Comparing the gut microbiota composition between kidney stone patients and healthy controls, with emphasis on analyzing the relative abundance of Lactobacillus salivarius\n2. Comparing the differences in tryptophan metabolite levels such as indole-3-carboxylic acid (ICA) and kynurenine (Kyn) in serum between the two groups\n3. Exploring the correlation between gut microbiota composition and tryptophan metabolite levels\n4. Analyzing the influence of different environmental conditions (seasons, temperature and humidity) on gut microbiota and metabolite levels",[29,304],"Ureteral Calculi","2026-01-18",{"date":307,"type":50},"2026-01-21",{"date":309,"type":21},"2026-09-01",{"date":311,"type":21},"2027-12-31",{"name":313,"class":57},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":4,"eligibilityCriteria":320,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":97,"enrollmentInfo":321,"targetDuration":4,"studyType":129,"phases":4,"briefSummary":322,"conditions":323,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":324,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":4},"100567382","new-laser-and-suction-sheath-for-kidney-stone-treatment-100567382","NCT06667466","New Laser and Suction Sheath for Kidney Stone Treatment","Prospective, Multicenter, Randomized Controlled Trial of Super Pulse Thulium Fiber Laser Combined With Flexible Negative Pressure Suction Sheath Versus Conventional Sheath for the Treatment of Kidney Stones","Inclusion Criteria:\n\n* Age ≥18 years old.\n* Diagnosed with kidney stones and\u002For ureteral stones, and stone diameter is ≥6mm and ≤20mm\n* Plan to undergo fURS lithotripsy\n* General anesthesia to complete the operation\n* The latest urine culture before surgery is negative\n* Signed and dated informed consent\n\nExclusion Criteria:\n\n* Isolated kidney\n* Previous history of kidney transplantation or urinary diversion surgery\n* Congenital malformations of urinary system\n* Abnormal coagulation mechanism due to blood system diseases, liver diseases, etc\n* Severe heart or lung disease, malignancy and immune deficiency status\n* Neurogenic bladder\n* Failure to provide informed consent\n* Have an untreated urinary tract infection\n* The presence of known anatomic abnormalities (such as ureteral stenosis), urothelial tumors, or stones that can be removed directly without the use of laser lithotripsy\n* Pregnant women\n* In cases where the stone cannot be reached with a bendable negative pressure suction sheath, or in cases where the stone cannot be reached with a conventional sheath or the pyeloureteral junction\n* Epidural anesthesia or lumbar anesthesia to complete the operation",{"count":99,"type":21},"The goal of this clinical trial is to learn if the combination of super pulsed thulium fiber laser (sTFL) with a flexible negative pressure suction sheath is more effective and safer than sTFL with a conventional sheath in treating kidney stones and\u002For ureteral stones. The main questions it aims to answer are:\n\nDoes the sTFL with a flexible negative pressure suction sheath have a higher stone - free rate than the sTFL with a conventional sheath? Does the sTFL with a flexible negative pressure suction sheath have fewer complications than the sTFL with a conventional sheath?\n\nResearchers will compare the two treatment groups to see if there are differences in stone - free rate and complication rates.\n\nParticipants will:\n\nUndergo ureteroscopic lithotripsy surgery. In the experimental group, have a flexible negative pressure suction sheath inserted along a guidewire to the stone site under general anesthesia, then have a ureteroscope inserted through the sheath to the stone site, and have the stone fragmented by sTFL with a power setting of 0.8J and a frequency of 12 - 20Hz while the fragments are removed by negative pressure suction.\n\nIn the control group, have a conventional sheath inserted to the upper ureter or the ureteropelvic junction under general anesthesia, then have a ureteroscope inserted through the sheath to the stone site, and have the stone fragmented by sTFL with a power setting of 0.8J and a frequency of 12 - 20Hz and the fragments removed by a stone basket.",[29,304],{"date":307,"type":50},{"date":326,"type":21},"2026-11-20",{"date":328,"type":21},"2027-11-20",{"name":313,"class":57},{"id":331,"slug":332,"hasResults":11,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":4,"eligibilityCriteria":336,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":97,"enrollmentInfo":337,"targetDuration":4,"studyType":129,"phases":4,"briefSummary":339,"conditions":340,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":341,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":58},"100567389","comparing-super-pulse-fiber-thulium-laser-and-holmium-laser-for-ureteral-stone-fragmentation-during-ureteroscopy-100567389","NCT06667557","Comparing Super Pulse Fiber Thulium Laser and Holmium Laser for Ureteral Stone Fragmentation During Ureteroscopy","Comparison of Super Pulse Fiber Thulium Laser and Holmium Laser Lithotripsy Under Ureteroscopy","Inclusion Criteria:\n\n* Age ≥18 years old\n* Diagnosis of kidney stones and\u002For upper ureteral stones with stone diameter ≥6mm and ≤20mm\n* Plan to undergo fURS lithotripsy\n* General anesthesia to complete the operation\n* The latest urine culture before surgery is negative\n* Signed and dated informed consent indicating that the patient or his or her legal representative has been fully informed about the study and has consented to participate\n\nExclusion Criteria:\n\n* Isolated kidney\n* Previous history of kidney transplantation or urinary diversion surgery\n* Congenital malformations of urinary system\n* Abnormal coagulation mechanism due to blood system diseases, liver diseases, etc.\n* Severe heart or lung disease, malignancy and immune deficiency status\n* Neurogenic bladder\n* Failure to provide informed consent\n* Have an untreated urinary tract infection\n* The presence of known anatomic abnormalities (such as ureteral stenosis), urothelial tumors, or stones that can be removed directly without the use of laser lithotripsy\n* Pregnant women\n* In cases where the stone cannot be reached with a bendable negative pressure suction sheath, or in cases where the stone cannot be reached with a conventional sheath or the pyeloureteral junction\n* Surgical completion under epidural anesthesia or lumbar anesthesia\n* Recurrent stones due to genetic metabolic diseases",{"count":338,"type":21},136,"The goal of this prospective, multicenter, randomized controlled trial is to objectively evaluate the clinical efficacy and safety differences between superpulse thulium fiber laser (sTFL) and holmium:YAG laser (Ho:YAG) in flexible ureteroscopy (FURS) lithotripsy in adult patients aged 18-70 years with kidney stones and\u002For upper ureteral stones (6-20mm). The main questions it aims to answer are:\n\nDoes sTFL yield a higher stone-free rate (SFR) compared to Ho:YAG at 3 months post-FURS? Is sTFL superior to Ho:YAG in terms of operation time, complication rate, and surgeon's visual experience during FURS? Researchers will compare the experimental group receiving sTFL treatment to the control group receiving Ho:YAG laser treatment to see if sTFL demonstrates better lithotripsy efficiency, safety, and ease of operation.\n\nParticipants aged 18-70 years will:\n\nUndergo FURS lithotripsy under general anesthesia using either sTFL (experimental group) or Ho:YAG laser (control group) based on randomization Have CT scans at 3 months post-operation to assess stone-free status Be monitored for intraoperative and postoperative complications Have surgeons rate their visual experience during the procedure in terms of visual clarity, lithotripsy efficiency, stone movement and tissue injury",[29],{"date":307,"type":50},{"date":343,"type":50},"2025-01-20",{"date":345,"type":21},"2028-10-20",{"name":313,"class":57},{"id":348,"slug":349,"hasResults":11,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":354,"targetDuration":4,"studyType":22,"phases":356,"briefSummary":357,"conditions":358,"keywords":359,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":58},"100611301","outcomes-of-using-fans-with-furs-in-ttt-of-lower-calyceal-stones-100611301","NCT07238803","Outcomes of Using FANS With FURS in TTT of Lower Calyceal Stones.","Outcomes of Using Flexible and Navigable Suction Sheath With Flexible Ureteroscopy in Treatment of Lower Calyceal Stones: A Prospective Study","Inclusion Criteria:\n\n1. Adult patients ≥ 18 years old.\n2. Patients with lower calyceal stones scheduled for FURS.\n\nExclusion Criteria:\n\n1. patients with active urinary tract infections.\n2. Patients with renal and ureteric anomalies.\n3. patients with coagulopathy\n4. patients who are refusing to participate.",{"count":355,"type":21},33,[24],"The aim of this study is to evaluate and assess the outcomes of flexible ureteroscopy (FURS) with flexible and navigable suction UAS (FANS) in the treatment of lower calyceal stones.",[186,29],[360],"Flexible Ureteroscopy","2025-11-18",{"date":363,"type":50},"2025-11-20",{"date":365,"type":50},"2024-12-01",{"date":367,"type":21},"2026-02-01",{"name":369,"class":370},"Zagazig University","OTHER_GOV",{"id":372,"slug":373,"hasResults":11,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":4,"eligibilityCriteria":377,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":22,"phases":380,"briefSummary":381,"conditions":382,"keywords":385,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":58},"100609207","the-larc-robot-simplifies-renal-access-in-percutaneous-nephrolithotomy-100609207","NCT07211555","The LARC Robot Simplifies Renal Access In Percutaneous Nephrolithotomy","The LARC Robot Simplifies Renal Access In Percutaneous Nephrolithotomy (PCNL)","Inclusion Criteria:\n\n* Kidney stones larger than 2 cm\n* Staghorn renal calculi\n* Lower pole stones less than 2 cm\n* Anatomical abnormalities that reduce the likelihood of spontaneous stone fragment passage, such as:\n* Horseshoe kidney\n* Calyceal diverticulum\n* Ectopic or dystopic kidney\n* Stones that are refractory to prior treatment (e.g., ESWL or ureteroscopy)\n* Suspected malignant tumors or masses located in the planned renal access tract\n\nExclusion Criteria:\n\n* Pregnancy\n* Active urinary tract infection (UTI) or untreated sepsis\n* Known bleeding disorders or uncorrectable coagulopathy despite medical management\n* Use of anticoagulant medications (e.g., warfarin, heparin, or DOACs) that cannot be safely discontinued\n* Allergy to contrast media that cannot be pre-medicated or managed\n* Severe cardiopulmonary comorbidities that contraindicate anesthesia or PCNL\n* Inability to provide informed consent\n* Participation in another investigational study that may interfere with study outcomes",{"count":379,"type":21},45,[24],"This study is being done to evaluate a new robotic system that helps urologists more precisely reach the kidney during surgery to remove large kidney stones. The procedure, called percutaneous nephrolithotomy (PCNL), is typically used for people who have large or difficult-to-remove kidney stones.\n\nTraditionally, many urologists rely on radiologists to place a tube into the kidney before surgery. This can cause delays, require multiple procedures, and increase costs. The robotic system being studied - called LARC - is designed to help the urologist safely and accurately guide a needle directly into the kidney during the surgery, without needing a separate procedure beforehand.\n\nThe robot uses live X-ray images to help align the instruments. Although parts of the robot have been approved by the U.S. FDA, the version used in this study is still investigational and not yet approved for this specific purpose.\n\nThe study will take place at AdventHealth Celebration and include up to 45 adult patients who are scheduled for PCNL surgery. Participants will be followed for up to 1 month after surgery, and doctors will look at outcomes such as the success of the procedure, the number of kidney stones removed, complications, time in surgery, and radiation exposure.\n\nThis research may help make kidney stone surgery safer, faster, and more effective in the future.",[383,29,384,106],"Renal Stone Disease","Refractory Kidney Stones",[386,387],"Robotic Surgery","Minimally Invasive Surgery","2025-09-30",{"date":390,"type":50},"2025-10-08",{"date":392,"type":21},"2025-11-01",{"date":394,"type":21},"2026-01-01",{"name":396,"class":57},"AdventHealth"]